ArticleTropical medicine and health2025
The economic burden of brucellosis in Western Iran.
Article in Tropical medicine and health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Frontline governance: a street-level bureaucracy perspective on brucellosis control in Western Iran.Tropical medicine and health · 2026Article
- Strengthening brucellosis prevention and control in Iran: policy priorities informed by stakeholder networks, agenda-setting dynamics, and economic burden evidence.Tropical medicine and health · 2026Article
- Spatiotemporal distribution characteristics and disease burden of human brucellosis in Inner Mongolia Autonomous Region, 2014-2023.Frontiers in public health · 2026Article
- Seroprevalence and associated risk factors of human brucellosis among occupational population in Binzhou, China: a cross-sectional study.Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBrucellosis, a zoonotic disease caused by Brucella species, remains a major public health and economic challenge in regions dependent on livestock farming. In Iran, particularly in the western provinces, the disease imposes a heavy burden on healthcare systems and households through medical costs and productivity losses. This study quantified the economic burden of brucellosis in western Iran to inform policy and resource allocation.
methodsA cross-sectional cost-of-illness study was conducted among 427 brucellosis patients in Lorestan province. Data on direct medical costs (hospitalization, medications, diagnostics), direct non-medical costs (transportation, accommodation), and indirect costs (productivity losses) were collected using a bottom-up approach. All costs were expressed in 2024 USD, and sensitivity analyses were conducted at 0% and 5% discount rates. The catastrophic health expenditure (CHE) index was used to assess financial hardship.
resultsThe mean total cost per patient was 1,060 USD, with direct medical costs representing 73.6% of the total. Hospitalization was the largest component (38%), followed by surgical interventions (26%) and medications (13%). Indirect costs accounted for 18.9% of the total burden. The CHE index reached 66.3%, indicating severe financial strain for affected households. Sensitivity analyses showed notable variability in medical and non-medical cost estimates.
conclusionBrucellosis imposes a substantial economic burden in western Iran, reflecting both healthcare and productivity losses. Effective control measures such as livestock vaccination, improved diagnosis, and expanded insurance coverage are essential to reduce financial hardship and support sustainable disease management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.